GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List

Range Low Price High Price Comment
30 days $0.87 $1.65 Thursday, 18th Apr 2024 ADAP stock ended at $0.90. This is 8.98% less than the trading day before Wednesday, 17th Apr 2024. During the day the stock fluctuated 13.44% from a day low at $0.87 to a day high of $0.99.
90 days $0.691 $2.05
52 weeks $0.420 $2.05

Historical Adaptimmune Therapeutics plc prices

Date Open High Low Close Volume
2024-04-18 $0.97 $0.99 $0.87 $0.90 3 323 777
2024-04-17 $1.02 $1.05 $0.93 $0.99 1 221 844
2024-04-16 $1.20 $1.20 $0.98 $1.03 1 224 075
2024-04-15 $1.20 $1.21 $1.05 $1.05 1 322 411
2024-04-12 $1.20 $1.28 $1.13 $1.16 3 033 667
2024-04-11 $1.28 $1.34 $1.26 $1.29 869 563
2024-04-10 $1.33 $1.33 $1.25 $1.27 1 449 671
2024-04-09 $1.36 $1.41 $1.35 $1.37 717 427
2024-04-08 $1.40 $1.40 $1.33 $1.36 1 018 208
2024-04-05 $1.39 $1.42 $1.32 $1.37 1 204 906
2024-04-04 $1.41 $1.45 $1.35 $1.35 774 904
2024-04-03 $1.40 $1.42 $1.35 $1.38 1 628 372
2024-04-02 $1.46 $1.46 $1.36 $1.40 1 110 910
2024-04-01 $1.55 $1.55 $1.45 $1.47 1 333 977
2024-03-28 $1.65 $1.65 $1.53 $1.58 1 066 010
2024-03-27 $1.55 $1.63 $1.47 $1.58 1 180 018
2024-03-26 $1.45 $1.57 $1.38 $1.52 1 193 755
2024-03-25 $1.45 $1.56 $1.42 $1.44 1 173 516
2024-03-22 $1.34 $1.48 $1.32 $1.44 1 663 925
2024-03-21 $1.29 $1.40 $1.29 $1.34 1 146 245
2024-03-20 $1.44 $1.44 $1.24 $1.33 3 076 279
2024-03-19 $1.45 $1.52 $1.38 $1.41 1 171 164
2024-03-18 $1.50 $1.51 $1.37 $1.47 1 092 073
2024-03-15 $1.47 $1.49 $1.42 $1.48 630 710
2024-03-14 $1.55 $1.56 $1.41 $1.46 1 336 801
Click to get the best stock tips daily for free!

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa... ADAP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT